Tommy Stryjewski, MD
Chief Scientific Officer & Cofounder
Biography
Dr. Stryjewski is co-founder of Pykus Therapeutics and serves as the Chief Scientific Officer and as a member of the board of directors. He received his medical degree with honors from Harvard Medical School and trained in internal medicine at Massachusetts General Hospital and in ophthalmology and vitreoretinal surgery at Massachusetts Eye and Ear Infirmary, where he also served as Chief Resident, Director of the Eye Trauma Service, and was a member of the Harvard Medical School faculty. He is a board certified retinal surgeon and continues to see patients at Tallman Eye Associates, a private practice in the Boston area. Previously, Dr. Stryjewski was co-founder and founding President of Helio Vision Inc. (Waltham, MA), which developed therapies for rare proliferative vitreoretinal diseases. Helio Vision was acquired by Aldeyra Therapeutics (Lexington, MA; Nasdaq: ALDX) in 2019.